HR LC-MS/MS metabolomic profiling of Yucca aloifolia fruit and the potential neuroprotective effect on rotenone-induced Parkinson's disease in rats.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Yucca* ; Neuroprotective Agents*/pharmacology ; Parkinson Disease*/drug therapy ; Parkinson Disease*/prevention & control; Male ; Animals ; Rats ; Anthocyanins ; Chromatography, Liquid ; Fruit ; Rotenone/toxicity ; Tandem Mass Spectrometry ; Plant Extracts/pharmacology

Yucca aloifolia L. fruit (Yucca or Spanish bayonet, family Asparagaceae) is recognized for its purplish red color reflecting its anthocyanin content, which has a powerful antioxidant activity. This study aimed to investigate yucca (YA) fruit extract's protective effect on Parkinson's disease (PD). In vitro study, the anti-inflammatory activity of yucca fruit extracts was explored by measuring tumor necrosis factor receptor 2 (TNF-R2) and nuclear factor kappa B (NF-KB) to choose the most effective extract. Afterward, a detailed in vivo investigation of the protective effect of the most active extract on rotenone-induced PD was performed on male albino Wister rats. First, the safety of the extract in two different doses (50 and 100 mg/kg in 0.9% saline orally) was confirmed by a toxicological study. The rats were divided into four groups: 1) normal control (NC); 2) rotenone group; and third and fourth groups received 50 and 100 mg/kg yucca extract, respectively. The neurobehavioral and locomotor activities of the rats were tested by rotarod, open field, and forced swim tests. Striatal dopamine, renal and liver functions, and oxidative stress markers were assessed. Western blot analysis of brain tissue samples was performed for p-AMPK, Wnt3a, and β-catenin. Histopathological examination of striatal tissue samples was performed by light and electron microscopy (EM). The metabolites of the active extract were characterized using high-resolution LC-MS/MS, and the results showed the prevalence of anthocyanins, saponins, phenolics, and choline. Biochemical and histopathological tests revealed a dose-dependent improvement with oral Yucca extract. The current study suggests a possible neuroprotective effect of the acidified 50% ethanol extract (YA-C) of the edible Yucca fruit, making it a promising therapeutic target for PD.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2023 Ali et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

BMC Complement Med Ther. 2020 Jan 23;20(1):20. (PMID: 32020857)
Adv Protein Chem Struct Biol. 2012;88:69-132. (PMID: 22814707)
Front Cell Neurosci. 2015 May 05;9:166. (PMID: 25999816)
Rapid Commun Mass Spectrom. 2004;18(5):553-63. (PMID: 14978800)
Int J Mol Sci. 2020 Nov 17;21(22):. (PMID: 33212797)
Nutrients. 2017 May 10;9(5):. (PMID: 28489058)
Rapid Commun Mass Spectrom. 2004;18(2):235-8. (PMID: 14745777)
Behav Brain Funct. 2020 Nov 6;16(1):9. (PMID: 33158454)
Nat Prod Commun. 2015 Jan;10(1):77-9. (PMID: 25920224)
J Biol Chem. 1951 Nov;193(1):265-75. (PMID: 14907713)
Pharmacol Rep. 2012;64(5):1081-90. (PMID: 23238465)
PLoS One. 2013 Jul 11;8(7):e68584. (PMID: 23874679)
Free Radic Biol Med. 2018 Dec;129:73-87. (PMID: 30176346)
J Oral Implantol. 2008;34(4):196-202. (PMID: 18780564)
J Pharm Biomed Anal. 2008 Aug 5;47(4-5):870-5. (PMID: 18407448)
Food Chem. 2014 Mar 1;146:289-98. (PMID: 24176345)
Plants (Basel). 2021 Sep 21;10(9):. (PMID: 34579502)
Sci Rep. 2020 Oct 20;10(1):17778. (PMID: 33082381)
Molecules. 2018 Apr 02;23(4):. (PMID: 29614843)
Evid Based Complement Alternat Med. 2012;2012:823206. (PMID: 21792372)
J Young Pharm. 2012 Jul;4(3):177-83. (PMID: 23112537)
J Enzyme Inhib Med Chem. 2016;31(3):389-97. (PMID: 25798687)
Int J Neurosci. 2014 Sep;124(9):673-84. (PMID: 24325390)
J Neuroinflammation. 2016 Nov 8;13(1):286. (PMID: 27821173)
J Ethnopharmacol. 2007 Jan 3;109(1):41-7. (PMID: 16930896)
Phytother Res. 2015 Feb;29(2):187-200. (PMID: 25408503)
J Assoc Off Anal Chem. 1988 Jul-Aug;71(4):785-8. (PMID: 3417602)
Nutrients. 2020 Jun 10;12(6):. (PMID: 32531929)
Behav Brain Res. 2007 Mar 28;178(2):221-8. (PMID: 17250903)
Antioxid Redox Signal. 2012 May 1;16(9):920-34. (PMID: 21554057)
Pharmacology. 1974;11(3):151-69. (PMID: 4831804)
Biochem Biophys Res Commun. 2010 Apr 23;395(1):146-51. (PMID: 20361929)
Invest Ophthalmol Vis Sci. 2012 Jun 20;53(7):3766-81. (PMID: 22531701)
Biomed Pharmacother. 2021 Aug;140:111556. (PMID: 34087694)
Molecules. 2021 Apr 17;26(8):. (PMID: 33920713)

0 (Anthocyanins)
0 (Neuroprotective Agents)
03L9OT429T (Rotenone)
0 (Plant Extracts)

Date Created: 20230228 Date Completed: 20230302 Latest Revision: 20230410

20230411

PMC9974117

10.1371/journal.pone.0282246

36854038